Specialty drugs in the United States (original) (raw)

About DBpedia

Specialty drugs or specialty pharmaceuticals are a recent designation of pharmaceuticals that are classified as high-cost, high complexity and/or high touch. Specialty drugs are often biologics—"drugs derived from living cells" that are injectable or infused (although some are oral medications). They are used to treat complex or rare chronic conditions such as cancer, rheumatoid arthritis, hemophilia, H.I.V. psoriasis, inflammatory bowel disease and hepatitis C. In 1990 there were 10 specialty drugs on the market, in the mid-1990s there were fewer than 30, by 2008 there were 200, and by 2015 there were 300. Drugs are often defined as specialty because their price is much higher than that of non-specialty drugs. Medicare defines any drug for which the negotiated price is $670 per month or m

Property Value
dbo:abstract Specialty drugs or specialty pharmaceuticals are a recent designation of pharmaceuticals that are classified as high-cost, high complexity and/or high touch. Specialty drugs are often biologics—"drugs derived from living cells" that are injectable or infused (although some are oral medications). They are used to treat complex or rare chronic conditions such as cancer, rheumatoid arthritis, hemophilia, H.I.V. psoriasis, inflammatory bowel disease and hepatitis C. In 1990 there were 10 specialty drugs on the market, in the mid-1990s there were fewer than 30, by 2008 there were 200, and by 2015 there were 300. Drugs are often defined as specialty because their price is much higher than that of non-specialty drugs. Medicare defines any drug for which the negotiated price is $670 per month or more, as a specialty drug which is placed in a specialty tier that requires a higher patient cost sharing. Drugs are also identified as specialty when there is a special handling requirement or the drug is only available via a limited distributions network. By 2015 "specialty medications accounted for one-third of all spending on drugs in the United States, up from 19 percent in 2004 and heading toward 50 percent in the next 10 years", according to IMS Health, which tracks prescriptions. According to a 2010 article in Forbes, specialty drugs for rare diseases became more expensive "than anyone imagined" and their success came "at a time when the traditional drug business of selling medicines to the masses" was "in decline". In 2015 analysis by The Wall Street Journal suggested the large premium was due to the perceived value of rare disease treatments which usually are very expensive when compared to treatments for more common diseases. (en) 美國特殊藥品(英語:specialty drugs/pharmaceuticals in the United States),简称特药(相对于普药),是對最近高成本,高度複雜和/或涉及需要醫事人員密切注意及照顧()的藥品所給予的名稱。特殊藥品通常是生物製藥,“從活細胞發展出的藥品” - 可透過注射或輸注方式施用(也有口服式)。這類藥品用於治療複雜或罕見慢性病,例如癌症、類風濕關節炎、血友病、人類免疫缺乏病毒(HIV)、銀屑病(牛皮癬)、 炎症性腸病 、和C型肝炎。 在美國市場,1990年有10種特殊藥品,到1990年代中期,增加到接近30種,到2008年有200種,而到2015年則有300種。這類藥品被定義為“特殊”的原因是因為它們的價格比非屬特殊藥品的價格高很多。聯邦醫療保險(Medicare)把議價後每月價格在670美元,或更高的藥品定義為特殊藥品,將這種藥品歸類在患者需要分攤較高費用的等級中。如果藥品需要特殊處理,或只能經由有限的分銷網絡取得,這類藥品也被視為特殊藥品。根據針對美國醫療衛生產業提供資訊、服務、和技術的公司所提供的數據,在2015年,“特殊藥品占美國藥品總支出的三分之一,從2004年的19%上升,往10年後佔50%的方向前進”。根據2010年《富比士》雜誌上的一篇文章,針對治療罕見疾病的特殊藥品變得“超乎人們想像的昂貴”,並且它們的成功正逢“提供給大眾的傳統藥品業務開始式微的時候”。華爾街日報》在2015年刊出的報導中臆測,這種大幅的差價是由於治療罕見疾病與治療常見疾病相比,被感知的價值就非常昂貴的緣故。 (zh)
dbo:wikiPageExternalLink https://www.cbo.gov/system/files/2019-03/54964-Specialty_Drugs.pdf
dbo:wikiPageID 48172434 (xsd:integer)
dbo:wikiPageLength 82351 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID 1124606830 (xsd:integer)
dbo:wikiPageWikiLink dbr:Cancer dbr:Capecitabine dbr:Catamaran_Corporation dbr:Prince_Edward_Island dbr:Psoriasis dbr:Public_Health_Service_Act dbr:Quincy,_M.E. dbr:Entitlement dbr:National_Comprehensive_Cancer_Network dbr:Bloomberg_News dbr:Delcath_Systems,_Inc. dbc:Biopharmaceuticals dbr:Humana dbr:Huntington's_disease dbr:Pfizer dbr:Rheumatoid_arthritis dbr:UnitedHealth_Group dbr:David_Charles_(physician) dbr:Intravenous_therapy dbr:Route_of_administration dbr:Prime_Therapeutics dbc:Biotechnology dbr:Congressional_Budget_Office dbr:Medicare_(United_States) dbr:Medicare_Prescription_Drug,_Improvement,_and_Modernization_Act dbr:Melphalan dbr:Chemical_patent dbr:National_Organization_for_Rare_Disorders dbr:Orphan_disease dbr:Orphan_drug dbr:Genentech dbr:Genzyme dbr:George_W._Bush dbr:Gilead dbr:Myoclonus dbr:The_Wall_Street_Journal dbr:Thomson_Reuters dbr:Malaria dbr:Shire_(pharmaceutical_company) dbr:Pacific_Rim dbr:Pharmacy_benefit_management dbr:Sterling_Drug dbr:Medicare_Part_D dbr:Avastin dbr:Busulfan dbr:CVS_Health dbr:Acthar dbr:Activase dbr:Centers_for_Medicare_and_Medicaid_Services dbr:Tourette_syndrome dbr:Tretinoin dbr:U.S._Food_and_Drug_Administration dbr:Walgreens dbr:Walgreens_Boots_Alliance dbr:Toxoplasmosis dbr:AARP dbr:AIDS dbr:Abstral dbr:Accredo dbr:Alexion_Pharmaceuticals dbr:Amyotrophic_lateral_sclerosis dbr:Drug_Price_Competition_and_Patent_Term_Restoration_Act dbr:Drug_development dbr:Eastman_Kodak_Company dbr:Eculizumab dbr:Express_Scripts dbr:Food_and_Drug_Administration_Amendments_Act_of_2007 dbr:Forbes dbr:Breakthrough_therapy dbr:Palbociclib dbr:Center_for_Biologics_Evaluation_and_Research dbr:Journal_of_Managed_Care_&_Specialty_Pharmacy dbr:Prescription_drug dbr:Risk_Evaluation_and_Mitigation_Strategies dbr:Henri_Termeer dbr:Hepatitis_C dbr:Herceptin dbr:Ivacaftor dbr:Jack_Klugman dbr:Federal_Food,_Drug_and_Cosmetic_Act dbr:Solodyn dbc:Life_sciences_industry dbc:Pharmaceutical_industry dbr:Academy_of_Managed_Care_Pharmacy dbc:Biotechnology_products dbc:Specialty_drugs dbr:Chemotherapy dbr:Biopharmaceutical dbr:Sun_Life_Financial dbr:High-touch dbr:Valeant dbr:Martin_Shkreli dbr:Philidor_Rx_Services dbr:H.I.V. dbr:IMS_Health dbr:Inflammatory_bowel_disease dbr:Michael_Constantine dbr:National_Center_for_Biotechnology_Information dbr:New_York_Times dbr:Omnicare dbr:Orphan_Drug_Act_of_1983 dbr:Breakthrough_Therapy dbr:World_Health_Organization's_List_of_Essential_Medicines dbr:Managed_care dbr:Patient_Protection_and_Affordable_Care_Act dbr:Institute_of_Medicine dbr:Muscular_dystrophy dbr:Jublia dbr:Patient-centered_care dbr:Lysosomal_acid_lipase_deficiency dbr:Office_of_Global_Regulatory_Operations_and_Policy dbr:Sovaldi dbr:The_American_Journal_of_Managed_Care dbr:Tarceva dbr:Rituxan dbr:Valeant_Pharmaceuticals dbr:Specialty_pharmacy dbr:Wall_Street_Journal dbr:Health_Insurance_Marketplace dbr:OptumRx dbr:Hemophilia dbr:Alliance_for_Patient_Access dbr:BioScrip dbr:CuraScript dbr:Curascript dbr:Don_M._Bailey dbr:Horizon_Pharma_Plc dbr:Institute_for_Integrated_Healthcare dbr:Linden_Care dbr:Medical_Science_Liaisons
dbp:date January 2017 (en)
dbp:reason vague (en)
dbp:wikiPageUsesTemplate dbt:According_to_whom dbt:Clarify dbt:Main dbt:Quote dbt:Reflist dbt:Rp dbt:Short_description
dcterms:subject dbc:Biopharmaceuticals dbc:Biotechnology dbc:Life_sciences_industry dbc:Pharmaceutical_industry dbc:Biotechnology_products dbc:Specialty_drugs
rdfs:comment Specialty drugs or specialty pharmaceuticals are a recent designation of pharmaceuticals that are classified as high-cost, high complexity and/or high touch. Specialty drugs are often biologics—"drugs derived from living cells" that are injectable or infused (although some are oral medications). They are used to treat complex or rare chronic conditions such as cancer, rheumatoid arthritis, hemophilia, H.I.V. psoriasis, inflammatory bowel disease and hepatitis C. In 1990 there were 10 specialty drugs on the market, in the mid-1990s there were fewer than 30, by 2008 there were 200, and by 2015 there were 300. Drugs are often defined as specialty because their price is much higher than that of non-specialty drugs. Medicare defines any drug for which the negotiated price is $670 per month or m (en) 美國特殊藥品(英語:specialty drugs/pharmaceuticals in the United States),简称特药(相对于普药),是對最近高成本,高度複雜和/或涉及需要醫事人員密切注意及照顧()的藥品所給予的名稱。特殊藥品通常是生物製藥,“從活細胞發展出的藥品” - 可透過注射或輸注方式施用(也有口服式)。這類藥品用於治療複雜或罕見慢性病,例如癌症、類風濕關節炎、血友病、人類免疫缺乏病毒(HIV)、銀屑病(牛皮癬)、 炎症性腸病 、和C型肝炎。 (zh)
rdfs:label Specialty drugs in the United States (en) 美國特殊藥品 (zh)
owl:sameAs wikidata:Specialty drugs in the United States yago-res:Specialty drugs in the United States dbpedia-zh:Specialty drugs in the United States https://global.dbpedia.org/id/2PDAh
prov:wasDerivedFrom wikipedia-en:Specialty_drugs_in_the_United_States?oldid=1124606830&ns=0
foaf:isPrimaryTopicOf wikipedia-en:Specialty_drugs_in_the_United_States
is dbo:wikiPageRedirects of dbr:Specialty_drug dbr:Specialty_drugs dbr:Specialty_drugs_(United_States)
is dbo:wikiPageWikiLink of dbr:Prescription_drug_prices_in_the_United_States dbr:Medicare_Part_D dbr:Amneal_Pharmaceuticals dbr:North_American_Free_Trade_Agreement dbr:Specialty_drug dbr:Specialty_drugs dbr:Specialty_drugs_(United_States) dbr:First-in-class_medication
is foaf:primaryTopic of wikipedia-en:Specialty_drugs_in_the_United_States